FIP1L1/PDGFRA 4q12 Rearrangement
Expected Turnaround Time
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
Requisition Forms
Specimen Requirements
Specimen Requirements
- Whole Blood: 5 mL, EDTA preferred (NaHep accepted)
- Bone Marrow Aspirate: 3 mL, EDTA preferred (NaHep accepted)
Specimen Stability
72 hours
Storage Requirements
- Whole Blood: 2°C to 25°C
- Bone Marrow Aspirate: 2°C to 25°C
- Fixed Cytogenetically Prepared Cells: -28°C to -15°C
Shipping Conditions
Shipping Recommendations
AMBIENT, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen. Do not freeze.
Specimen Rejection Criteria
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells; Improper fixative.
Test Details
Synonyms
4q12 rearrangement, CHIC2/F1LP1L1/PDGFRα, platelet-derived growth factor receptor-α, platelet-derived growth factor receptor alpha, FIP1, RHE, PDGFR2, RHEPDGFRA, FIP1L1-PDGFRA fusion
Keywords
Test Method
Methodology Category
Regulatory Status
Special Considerations
All attempts will be made to process and report samples received > 72 hours post-collection. Bone marrow is the sample of choice in most heme malignancies.
Associations
Hypereosinophilia, Mast cell
Get Expert Guidance on FIP1L1/PDGFRA 4q12 Rearrangement
Our laboratory specialists can help you understand test requirements, methodology, and interpretation.
Connect with an Expert Today